EP2318411A2 - Kristalline salze von sitagliptin - Google Patents

Kristalline salze von sitagliptin

Info

Publication number
EP2318411A2
EP2318411A2 EP09772169A EP09772169A EP2318411A2 EP 2318411 A2 EP2318411 A2 EP 2318411A2 EP 09772169 A EP09772169 A EP 09772169A EP 09772169 A EP09772169 A EP 09772169A EP 2318411 A2 EP2318411 A2 EP 2318411A2
Authority
EP
European Patent Office
Prior art keywords
sitagliptin
acid
xrpd pattern
characteristic peaks
pattern characteristic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP09772169A
Other languages
English (en)
French (fr)
Inventor
Ramesh Matioram Gidwani
Channaveerayya Hiremath
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ratiopharm GmbH
Original Assignee
Ratiopharm GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41130354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2318411(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ratiopharm GmbH filed Critical Ratiopharm GmbH
Priority to EP14190672.7A priority Critical patent/EP2915814A3/de
Priority to PL12193696T priority patent/PL2586782T5/pl
Priority to EP13175630.6A priority patent/EP2650297A1/de
Priority to EP13175631.4A priority patent/EP2650298A1/de
Priority to EP12193696.7A priority patent/EP2586782B2/de
Priority to EP13175629.8A priority patent/EP2650296A1/de
Priority to EP13175633.0A priority patent/EP2650299A1/de
Publication of EP2318411A2 publication Critical patent/EP2318411A2/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Definitions

  • the present invention relates to crystalline monobasic, dibasic and tribasic acid addition salts of the dipeptidyl peptidase-IV inhibitor sitagliptin.
  • the enzyme dipeptidyl peptidase-IV (DPP-IV) is responsible for the degradation of incretins such as the glucagon-like peptide-l (GLP-I) and the gastric inhibitory polypeptide (GIP), also known as the glucose-dependent insulinotropic peptide.
  • DPP-IV dipeptidyl peptidase-IV
  • GLP-I glucagon-like peptide-l
  • GIP gastric inhibitory polypeptide
  • NIDDM non-insulin dependent diabetes mellitus
  • EP 0 896 538 describes the use of a DPP-IV inhibitor to lower the blood glucose level in mammals.
  • WO 2003/004498 teaches ⁇ -amino-tetrahydroimidazo-(1 ,2a)-pyrazine and ⁇ -amino- tetrahydroimidazolo-(4,3a)-pyrazine as dipeptidyl peptidase inhibitors for the therapy and prevention of diabetes.
  • One of these pyrazines is sitagliptin (7-[(3f?)-3-amino-1-oxo-4- (2,4,5-trifluorophenyl)butyl]-5 > 6,7,8-tetrahydro-3-(trifluoromethyl)-1 ,2,4-triazolo[4,3- a]pyrazine) having the following structural formula:
  • a list of pharmaceutical acceptable salts is generally included in WO 03/004498.
  • the crystalline salts of the present invention are not disclosed therein.
  • WO 2005/072530 discloses specific crystalline salts of sitagliptin and hydrochloric acid, benzene sulfonic acid, p-touluene sulfonic acid, D- and L-tartaric acid and (1 S)-(+)- and (1 ft)-(-)-10-camphorsulfonic acid.
  • WO 2005/003135 discloses sitagliptin dihydrogenphosphate and its crystalline mono- hydrate. Four crystalline polymorphs of sitagliptin dihydrogenphosphate anhydrate are disclosed in WO 2005/020920 and WO 2005/030127. Amorphous sitagliptin dihydrogenphosphate is claimed in WO 2006/ 033848.
  • the salts should be stable, preferably they should show a higher stability than the salts of the prior art and lower hygroscopicity.
  • sitagliptin in a form having a good chemical and/or physical stability, a low hygroscopicity, a good solubility, a good bioavailability and/or has a good processability, both during its preparation and in the preparation of pharmaceutical compositions containing the sitagliptin. It has now been found that one or more of the above problems can be solved by providing sitagliptin in the form of a crystalline salt with a monobasic, dibasic or tribasic acid.
  • the present invention relates to a crystalline salt of sitagliptin with a monobasic, dibasic or tribasic acid.
  • the crystalline salt of the present invention can be solvent free or can contain solvent molecules in its crystal structure.
  • the present invention also covers any hydrate or anhydrate or solvate form of the crystalline salt of sitagliptin.
  • the acid in the crystalline salt of the present invention may, for example, be selected from HCI, H 2 SO 4 , H 3 PO 4 , sulfonic acids, such as methanesulfonic acid, as well as mono, di and tricarboxylic acids.
  • the acid is not H 3 PO 4 .
  • the acid is a carboxylic acid, it can be of the general structural formula R 1 -COOH wherein R 1 is hydrogen, carboxyl, C 1-4 alkyl or C 2 ⁇ alkenyl, wherein the C 1-4 alkyl and the C 2-4 alkenyl may optionally be substituted with 1-2 carboxyl, 1-3 hydroxyl, 1-3 amino, 1-3 phenyl and/or 1-3 C 1-S alkyl.
  • alkyl and alkenyl groups may be linear or branched or, if it contains at least three carbon atoms, may form a ring.
  • the alkyl groups may, for example, be methyl, ethyl, propyl, n-butyl, tert-butyl and pentyl.
  • Preferred acids of the above general structural formula R 1 -COOH are those, wherein R 1 is C 2 alkyl or C 2 alkenyl each of which is substituted with 1 carboxyl and optionally with 1 hydroxyl or amino. Tartaric acid is preferably not employed.
  • carboxylic acids examples include fumaric acid, malonic acid, malic acid, succinic acid, lactic acid, glycolic acid, maleic acid, citric acid, aspartic acid and mandelic acid.
  • Examples for a dicarboxylic acids are succinic acid, malonic and fumaric acid, D- and L- tartaric acid, D- and L-malic acid and L-aspartic acid.
  • One example for a tribasic acid is citric acid.
  • Examples of monocarboxylic acids are glycolic acid and lactic acid.
  • Yet another embodiment of the present invention concerns a sitagliptin salt in which sitagliptin and the acid are substantially in a 1 :1 acid to base stoichiometry wherein the dibasic or tribasic acid is only singly deprotonated.
  • a novel form of sitagliptin hydrochloride is described.
  • the new polymorph of sitagliptin hydrochloride is characterised by DSC and XRD. DSC shows onset of melting transition point at 195.8 0 C ⁇ 2 0 C, and a peak melting point at 202.3 0 C ⁇ 2 °C as measured by DSC.
  • sitagliptin hydrochloride salt of the present invention shows a pH of 5.8 ⁇ 0.1 in 2 % aqueous solution. Further, the novel form of sitagliptin hydrochloride salt is not hygroscopic even under prolonged storage at 93 % relative humidity. Further, sitagliptin hydrochloride salt of the present invention shows excellent stability when stored at 60 0 C for 4 weeks.
  • sitagliptin hemisulfate is described.
  • the ratio of sitagliptin to sulfuric acid is 2:1.
  • Sitagliptin hemisulfate form Il is characterised by DSC and XRD.
  • DSC shows onset of melting transition at 169.3 0 C ⁇ 2 0 C, and a peak melting point at 175.9 0 C ⁇ 2 0 C as measured by DSC.
  • sitagliptin hemisulphate salt of present invention shows excellent stability when stored at 60 0 C for 4 weeks.
  • the sulfate salt shows very high solubility in water as compared to other known salts of sitagliptin.
  • polymorphs or crystalline sitagliptin salts of the present invention are described in the examples. These polymorphs are characterized by their DSC data and/or their XRPD data. In one embodiment these polymorphs are characterized by three characteristic peaks in the XRPD pattern at the 2 theta angles given in the claims for each of the polymorphs. In a further embodiment these polymorphs are characterized by the 2 theta angles of the five peaks in the XRPD pattern having the highest intensities. Most preferably, the polymorphs are characterized by the XRPD patterns as shown in the figures.
  • Another embodiment of the present invention is a pharmaceutical formulation comprising one or more salts of the present invention and a pharmaceutically acceptable carrier or diluent.
  • Another embodiment of the present invention is a pharmaceutical formulation comprising a combination of one or more salts of the present invention and one or more active pharmaceutical ingredients for the simultaneous, separate or sequential use in the therapy.
  • active pharmaceutical ingredients are anti-diabetics, e.g., metformin, pioglitazone or rosiglitazone.
  • Yet another embodiment of the present invention is the use of the sitagliptin salts for the preparation of a medicament for the treatment or prevention of non insulin dependent diabetes mellitus, obesity, insulin resistance, syndrome X and type 2 diabetes.
  • Another aspect of the present invention is a process for the preparation of a sitagliptin salt of the present invention comprising the steps of
  • the sitagliptin salts of the present invention exhibit improved properties compared to the free base.
  • the sitagliptin salts of the present invention are more stable and of improved quality compared to the free base, which is advantageous for the storage of raw material as well as for the distribution of the final product.
  • the salts of the present invention exhibit a higher solubility in aqueous solution, in particular under physiological conditions, compared to the free base or the phosphate salt. These properties are advantageous because the dissolution is faster and a smaller amount of water is needed for complete solvation. This may lead to a higher bioavailability compared to the free base, especially in the case of solid dosage forms.
  • sitagliptin salts of prior art Compared to sitagliptin salts of prior art, the novel sitagliptin salts exhibit a lower hygroscopicity. This leads to an improved stability due to reduced decomposition caused by hydrolysis.
  • the pharmaceutical sector there is a constant need for sitagliptin salts with improved stability, which can be further processed to a pharmaceutical formulation.
  • these salts shall be at least as stable as salts of the prior art and show a low hygroscopicity.
  • the sitagliptin salts of the present invention exhibit a lower tendency to decomposition by hydrolysis.
  • an aqueous solution of 0.020 kg sitagliptin in 1 litre of water shows a pH of 4-7, preferably 4.5-6.0.
  • the sitagliptin salts of the present invention have an improved solubility and are preferentially suitable for direct compression. Due to their superior crystallinity the salts of the present invention are especially suitable for the preparation of tablets with good solubility.
  • the sitagliptin salts of the present invention have very high chiral purity wherein the chiral purity is typically between 99 % and 100 %.
  • sitagliptin salts of the present invention can be prepared from the free base by methods known to those skilled in the art.
  • salts can be prepared by reaction of the free base with the respective acid in water or suitable organic solvents or in a mixture of water and one or more suitable organic solvents.
  • sitagliptin salts of the present invention can be prepared by reacting a sitagliptin salt of a first acid with a second acid, provided that the second acid is stronger and sets free the first, weaker acid.
  • non-aqueous solvents examples include ethers, preferably diethyl ether, esters, preferably ethyl acetate, alcohols, preferably ethanol and iso-propanol, and acetonitrile.
  • Preferred organic solvents are those which are at least partially miscible with water. Examples for such solvents are alcohols, for example methanol, ethanol, n-propanol, iso-propanol, and butanol, ketones, preferably acetone or methyl ethyl ketone, acetonitrile, dimethyl formamide (DMF), and dimethyl sulfoxide (DMSO).
  • the proportion of organic solvents is between 10% and 90%, preferably between 20% and 70%, most preferably between 30% and 50%.
  • the percentage of the organic solvent can be lower.
  • the crystallization is induced by addition of at least one seed crystal.
  • the solution can be cooled.
  • Yet another embodiment of the invention comprises the use of an anti-solvent. By adding an anti-solvent the solubility of a salt in a certain solvent is reduced.
  • anti- solvents examples include C 3-7 alkyl nitriles, in particular acetonitrile, esters, C 2-7 alkyl carbonic acid C 1-5 alkyl esters, in particular acetic acid ethyl ester or acetic acid isopropyl ester, di-(d-C 5 - alkyl)-ether, for example methyl tert.-butyl ether (MTBE), and tetrahydrofurane (THF), C 5 - C 8 -alkanes, in particular pentane, hexane or heptane. MTBE is especially preferred.
  • the salts may also have the advantage that they are more efficacious, less toxic, longer acting, have a broader range of activity, more potent, produce fewer side effects, more easily absorbed than, or have other useful pharmacological properties over, sitagliptin salts known in the prior art.
  • Such advantages can also particularly occur during combination therapy with a further active ingredient e.g. a second anti-diabetic agent such as metformin, pioglitazone, or rosiglitazone or an anti-hypertensive agent such as valsartan or in combination with a statin.
  • the salts of the present invention may be solvent-free, preferentially free of water.
  • the sitagliptin salts of the present invention are in the form of hydrates of solvates, for example hemi-, mono-, di-, tri-, tetra-, penta-, or hexa-solvates or - hydrates, respectively.
  • the solvents used for the crystallisation process in particular alcohols, preferably methanol or ethanol, ketones, esters, preferably ethyl acetate, can be embedded in the crystal structure.
  • the solvent is pharmaceutically acceptable.
  • a pharmaceutical composition including a sitagliptin salt of the present invention, in admixture with a pharmaceutically acceptable excipient or carrier.
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders and granules.
  • the active compound is typically mixed with at least one inert, pharmaceutically acceptable excipient or carrier, fillers or extenders, binders, humectants, disintegrating agents, and lubricants.
  • the compounds of the invention may be orally active, have rapid onset of activity and low toxicity.
  • a compound of the invention is preferably in the form of a tablet, preferably one obtainable by direct compression.
  • Figure 1 shows the XRPD pattern of sitagliptin HCI Form I.
  • Figure 2 shows the XRPD pattern of sitagliptin HCI Form II.
  • Figure 3 shows the XRPD pattern of sitagliptin fumarate Form I.
  • Figure 4 shows the XRPD pattern of sitagliptin fumarate Form II.
  • Figure 5 shows the XRPD pattern of sitagliptin malate.
  • Figure 6 shows the XRPD pattern of sitagliptin sulfate Form I
  • Figure 7 shows the XRPD-pattern of sitagliptin sulfate Form II.
  • Figure 8 shows the XRPD pattern of sitagliptin phosphate.
  • Figure 9 shows the XRPD pattern of sitagliptin succinate Form I.
  • Figure 10 shows the XRPD pattern of sitagliptin succinate Form II.
  • Figure 11 shows the XRPD pattern of sitagliptin succinate Form III.
  • Figure 12 shows the XRPD pattern of sitagliptin lactate.
  • Figure 13 shows the XRPD pattern of sitagliptin glycolate.
  • Figure 14 shows the XRPD pattern of sitagliptin maleate Form I.
  • Figure 15 shows the XRPD pattern of sitagliptin maleate Form II.
  • Figure 16 shows the XRPD pattern of sitagliptin citrate.
  • Figure 17 shows the XRPD pattern of sitagliptin mesylate Form I.
  • Figure 18 shows the XRPD pattern of sitagliptin mesylate Form II.
  • the samples were characterized by X-ray powder diffraction (XRPD) and differential scanning calometry (DSC).
  • the sample were, if necessary, grinded in a mortar from agate and properly prepared (flatted surface in z ⁇ ) on a specimen holder made from PMMA.
  • the samples were then analyzed on a Bruker-AXS D8 Advance powder X-ray diffractometer (Bruker-AXS, Düsseldorf, Germany).
  • the specimen holder was rotated in the z ⁇ plane at 20 rpm during measurement.
  • the measurement conditions were as follows: Radiation: Cu Ka, Source 40 kV / 40 mA, divergence slit 0.6 mm, detector: Vantec-1 anti-scattering slit 5.59 mm, detector slit 10.28 mm, start angle 2 °, end angle 55°, Step 0.016° 20.
  • Raw data were evaluated using the program EVA (Bruker-AXS, Düsseldorf, Germany).
  • the 2 theta angles are given with two ore more decimal places. However, the actual accuracy of the measurement is lower and, therefore, all 2 theta angles should be mathematically rounded to one decimal place. For example, a 2 theta angle of 6.562° is to be rounded to 6.6°. Moreover, in all cases an error of ⁇ 0.2° is to be assumed. The same is true for the d value, which is given in Angstrom and which should be rounded to one decimal place and having an error of ⁇ 0.2 Angstrom.
  • a Mettler Toledo 822e DSC instrument was used to record the DSC curves.
  • a sample amount of 1.5 to 2 mg was placed in the calorimeter cell and heated from 30°C to 300°C with a rate of 10°C/min and a nitrogen flow of 50 ml/min.
  • the results of the DSC experiments are summarized in tables 25-27.
  • sitagliptin free base (8.0 g, 19.65 mmol) was dissolved in 80 ml isopropanol. The reaction was stirred on a magnetic stirrer to give a clear solution. Aqueous hydrochloric acid 2.4 ml (30%) was added drop wise over a period of 10 minutes and was allowed to stir at room temperature. In the next 15 minutes a thick white precipitate was observed. An additional 40 ml of isopropanol was added to facilitate the stirring for a further 20 minutes and was filtered and dried at 60 °C for 3 h at 5 mbar vacuum to obtain 8.0 g (92.4 % yield) of white powder of sitagliptin hydrochloride. The residual solvent content was 2.02 % isopropanol as determined by headspace GC.
  • sitagliptin hydrochloride 7.5 g, white powder
  • 50 ml of ethanol 50 ml of ethanol
  • the clear solution was kept at room temperature for overnight for crystallization.
  • a thick cluster of white precipitate was observed in the flask and was filtered over a B ⁇ chner funnel and dried at 60 0 C for 4h at 5 mbar vacuum on a rotary evaporator to obtain 6.27 g of Sitagliptin hydrochloride.
  • product obtained is mixture of two forms of Sitagliptin hydrochloride, it should be recrystallised from ethyl acetate.
  • Sitagliptin free base (8.0 g, 19.65 mmol) was dissolved in 80 ml of ethyl acetate in a two neck flask. The reaction mixture was warmed at 50 0 C for about 7 minutes on a water bath to obtain clear solution and stirred using a teflon blade/mechanical stirrer at 200 rpm.
  • fumaric acid (2.286 g, 19.65 mmol) was dissolved in a mixture 80.0 ml of ethyl acetate and 60.0 ml of isopropanol and warmed over the water bath at 50 °C for 5 min to obtain a clear solution.
  • Fumaric acid solution was transferred in a dropping funnel and added dropwise to the Sitagliptin free base solution over a period of 6 min with a stirring speed of 305 rpm.
  • the temperature of the reaction was increased by 1.2 0 C (25.5 to 26.7°C).
  • the clear solution turned turbid during addition and during the following five minutes a thick precipitate separated out. This was stirred for a period of 30 minutes and filtered and dried at 70 0 C/ 3 h / 5 mbar vacuum to obtain 9.42 g (91%) of Sitagliptin fumarate.
  • Sitagliptin free base (7.0 g, 17.199 mmol) was dissolved in 70 ml of ethyl acetate and warmed at 60 °C on a water bath to obtain a clear solution while stirring on a magnetic stirrer.
  • L-malic acid (2.306 g, 17.199 mmol) and 14.0 ml of ethanol were mixed and warmed on the water bath at 60 0 C for 2 min to obtain a clear solution.
  • the clear solution of malic acid was transferred in a dropping funnel and added dropwise to the solution of Sitagliptin free base over a period of 5 min.
  • the clear solution was seeded with a crystalline sitagliptin malate sample derived from a previous experiment and stored for the crystallization. After two days the crystallized salt was scraped, filtered and dried at 70 0 C/ 3 h / 5 mbar vacuum to obtain 8.7 g of Sitagliptin malate.
  • DSC shows two peaks at 136.6 ⁇ 2°C (minor peak) and 153.5 ⁇ 2°C (major peak).
  • Sitagliptin free base (8.0 g, 19.65 mmol) was dissolved in 50 ml of ethanol. The reaction mass was warmed at 50 0 C on a water bath for 5 min to obtain a clear solution and was placed over a magnetic stirrer. In another flask sulfuric acid (98%, 0.9639 g, 9.828 mmol) and 30.0 ml of ethanol were mixed to make a clear solution. The clear solution of H 2 SO 4 was transferred in a dropping funnel and added dropwise over to a solution of Sitagliptin free base over a period of 6 min. The reaction mixture was stirred for 10 minutes and a white precipitate started emerging out and turned thick.
  • Sitagliptin sulfate (0.530 g, derived from example 6) was dissolved in 0.5 ml of water and the solution was kept in a freezer for 2 h and then kept at ambient temperature for 2 days for crystallization. The compound was dried 60 0 C for 2 h and 40 0 C for overnight.
  • Sitagliptin free base (8.0 g, 19.65 mmol) was dissolved in 20 ml of ethanol and warmed at 50 0 C on a water bath for 5 min to obtain a clear solution.
  • the clear solution was stirred at room temperature using a magnetic stirrer.
  • sitagliptin free base (10.0 g, 24.570 mmol) was dissolved in 30 ml of ethyl acetate and warmed to 70 0 C over a water bath to obtain clear solution and stirred using a magnetic stirrer.
  • succinic acid (2.9 g, 24.557 mmol) was dissolved in 16 ml of ethanol and warmed over the water bath at 50 °C for 5 min to obtain a clear solution. This solution was transferred in a dropping funnel and added dropwise over a period of 5 min to the sitagliptin free base solution.
  • To the clear solution 22.0 ml of n- hexane were added and the mixture was stored for crystallization.
  • the first crop was 1.95 g; having a DSC peak at 126.1 0 C ⁇ 2 0 C which is characteristic of sitagliptin succinate Form I.
  • the third crop yielded 4.90 g with DSC peaks at 124.2 ⁇ 2°C and 136.3 ⁇ 2 0 C in ratio of 75 :25 of Form I and Form Il respectively.
  • sitagliptin free base (4.0 g, 9.828 mmol) was dissolved in 12.0 ml of ethyl acetate and warmed to 60 °C over a water bath to obtain clear solution and stirred using a magnetic stirrer.
  • succinic acid (1.16 g, 10.0 mmol) was dissolved in 6 ml of ethanol and warmed over the water bath at 50 0 C for 5 min to obtain a clear solution. This solution was transferred in a dropping funnel and added dropwise over a period of 5 min to the sitagliptin free base solution.
  • sitagliptin succinate salt (derived from example 9) and stored for crystallization. This precipitate was filtered and dried at 60 0 C for 3 h. This yielded 4.9 g of sitagliptin succinate.
  • the sitagliptin succinate salt of this example can, if desired, be further purified to remove traces of an impurity of another polymorphic form having a DSC peak at 133.3 0 C ⁇ 2°C.
  • sitagliptin succinate salt of this example was added 50 ml of ethyl acetate and stirred at room temperature for 2 h and was filtered and dried at 60 0 C for 3 h.
  • the yield was 4.2 g sitagliptin succinate having a DSC peak at 167.8 0 C ⁇ 2 0 C.
  • sitagliptin free base (10.0 g, 24.57 mmol) was dissolved in 40 ml of ethyl acetate and warmed to 50 0 C over a water bath to obtain clear solution and stirred using a magnetic stirrer.
  • L-lactic acid (88%, 2.5 g, 24.20 mmol) was dissolved in 10.0 ml of ethyl acetate to obtain a clear solution.
  • This solution was transferred into a dropping funnel and added dropwise over a period of 5-7 min.
  • the clear solution began turning turbid in the first 10 min then became a thick precipitate with an increase of temperature of the reaction mixture by 2 0 C.
  • To filter this precipitate an additional 60.0 ml of ethyl acetate can be added and filtered. Drying was done at 60 0 C for 1h and at 80 0 C for 2h at 1 mbar vacuum.
  • sitagliptin free base 7.0 g, 17.99 mmol
  • sitagliptin free base 7.0 g, 17.99 mmol
  • glycolic acid 1.307 g, 17.99 mmol
  • This solution was transferred into a dropping funnel and added dropwise over a period of 5-7 min.
  • the clear solution turned turbid in the first 10 min and a thick mass precipitated.
  • sitagliptin free base 7.0 g, 17.19 mmol
  • sitagliptin free base 7.0 g, 17.19 mmol
  • 16 ml of ethanol 16 ml
  • 50 0 C 50 0 C
  • 4.0 ml of ethanol 4.0 ml
  • This solution was transferred into a dropping funnel and added drop wise to the sitagliptin solution over a period of 5 min with a stirring speed of 305 rpm.
  • the clear solution was kept overnight for crystallization.
  • the solution can be seeded with sitagliptin maleate salt crystals derived from a previous experiment.
  • the solid On the next day the solid had separated out and was filtered. 50 ml diisopropyl ether can be used to aid the filtration.
  • the filter cake was dried at 50 0 C for 1 h and at 60 0 C for 1 h at 5 mbar vacuum to obtain 9.00 g of sitagliptin maleate.
  • sitagliptin maleate (2.6 g, from example 13) was suspended in 50 ml of ethyl acetate and was stirred over a magnetic stirrer for 30 min and allowed to stand for 1 h. Sitagliptin maleate precipitated and was filtered. 10 ml of ethyl acetate was added to aid the filtration and the filter cake was dried at 60 0 C for 3 h.
  • the yield was 2.54 g sitagliptin maleate having a DSC peak at 159.5 0 C ⁇ 2 0 C.
  • sitagliptin free base 2.0 g, 4.91 mmol
  • citric acid 0.44 g 4.91 mmol
  • the solution was seeded with a sitagliptin citrate crystal and kept aside for crystallization. After three days the first crop was filtered and the mother liquor was kept for further crystallization. Since the crystallization was slow 10 ml of ethyl acetate was added as an anti-solvent and the crystallization was continued.
  • the first crop yielded 1.0 g of sitagliptin citrate having a DSC peak at 163.1 0 C ⁇ 2 0 C.
  • sitagliptin free base 5.Og, 12.28mmol
  • a solution of anhydrous citric acid (2.36 g, 12.28 mmol) in 20 ml ethyl acetate and 6 ml ethanol was added dropwise over a period of 5 min. A thick white precipitate was observed during the addition.
  • 10 ml of 2- propanol was added and reaction mass was evaporated to dryness to give 7.39 g of sitagliptin citrate. It was confirmed by DSC and XRD that the salt is amorphous.
  • Example 17 Sitagliptin Mesylate Form I and Sitagliptin Mesylate Form Il
  • Sitagliptin free base (6.0 g, 14.742 mmol) was dissolved in 24 ml of ethyl acetate and warmed to 65 0 C over a water bath to obtain a clear solution.
  • a solution of methanesulphonic acid (1.4167 g, 14.742 mmol) in 3.0 ml of ethanol was added dropwise over a period of 5 min.
  • the clear solution was kept overnight for crystallization.
  • the solution can be seeded with crystalline sitagliptin methanesulphonate salt in order to improve crystallisation.
  • the first crop crystallised after 2 days yielded 2.94 g of sitagliptin mesylate form I having a DSC peak at 125.0 0 C ⁇ 2°C.
  • the ethanol content was 2.97 % indicating that sitagliptin mesylate form I is an ethanol solvate.
  • a third crop yielded 3.16 g of sitagliptin mesylate form Il having a DSC peak at 161.8 0 C ⁇ 2 0 C. According to the residual solvent analysis of the third crop no residual ethanol was present.
  • the salts of the present invention and the free base were studied under three different humidity conditions (43 % relative humidity, 75 % relative humidity, and 93 % relative humidity). The results are summarized in tables 19-20.
  • the free base, phosphate monohydrate, phosphate, fumarate form I, malate, and maleate did not show much change during the hygroscopicity studies which was also confirmed by DSC of the samples kept at 93 % relative humidity for 2 weeks.
  • the new sitagliptin sulfate (non solvated; Table 21) showed an increase in water content corresponding to conversion of hemihydrate to dihydrate. DSC also showed an increase in peak due to water uptake.
  • the stability of the sitagliptin salts of the present invention and the free base were studied by storage of samples at 60 0 C for 2 and 4 weeks in closed bottles and storage at 40 0 C and 75 % relative humidity (RH) in an open bottle for 12 weeks.
  • the samples were analyzed by HPLC and the content of related substances, which are due to degradation of the sitagliptin, is summarized in tables 22-24.
  • the crystalline salts of the present invention can be formulated into a tablet by a direct compression process.
  • a 50 mg potency tablet is composed of: 73.58 mg of sitagliptin citrate, 176 mg mannitol, 5 mg of croscarmellose sodium, and 6 mg of magnesium stearate.
  • the active ingredient, microcrystalline cellulose, and croscarmellose are first blended, and the mixture is then lubricated with magnesium stearate and pressed into tablets.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP09772169A 2008-07-03 2009-07-02 Kristalline salze von sitagliptin Withdrawn EP2318411A2 (de)

Priority Applications (7)

Application Number Priority Date Filing Date Title
EP14190672.7A EP2915814A3 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
PL12193696T PL2586782T5 (pl) 2008-07-03 2009-07-02 Krystaliczne sole sitagliptyny
EP13175630.6A EP2650297A1 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
EP13175631.4A EP2650298A1 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
EP12193696.7A EP2586782B2 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
EP13175629.8A EP2650296A1 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
EP13175633.0A EP2650299A1 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1631CH2008 2008-07-03
PCT/EP2009/004767 WO2010000469A2 (en) 2008-07-03 2009-07-02 Crystalline salts of sitagliptin

Related Child Applications (2)

Application Number Title Priority Date Filing Date
EP14190672.7A Division EP2915814A3 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
EP12193696.7A Division EP2586782B2 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin

Publications (1)

Publication Number Publication Date
EP2318411A2 true EP2318411A2 (de) 2011-05-11

Family

ID=41130354

Family Applications (7)

Application Number Title Priority Date Filing Date
EP13175631.4A Withdrawn EP2650298A1 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
EP14190672.7A Withdrawn EP2915814A3 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
EP09772169A Withdrawn EP2318411A2 (de) 2008-07-03 2009-07-02 Kristalline salze von sitagliptin
EP13175633.0A Withdrawn EP2650299A1 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
EP13175630.6A Withdrawn EP2650297A1 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
EP13175629.8A Withdrawn EP2650296A1 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
EP12193696.7A Active EP2586782B2 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin

Family Applications Before (2)

Application Number Title Priority Date Filing Date
EP13175631.4A Withdrawn EP2650298A1 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
EP14190672.7A Withdrawn EP2915814A3 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin

Family Applications After (4)

Application Number Title Priority Date Filing Date
EP13175633.0A Withdrawn EP2650299A1 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
EP13175630.6A Withdrawn EP2650297A1 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
EP13175629.8A Withdrawn EP2650296A1 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin
EP12193696.7A Active EP2586782B2 (de) 2008-07-03 2009-07-02 Kristalline Salze von Sitagliptin

Country Status (9)

Country Link
EP (7) EP2650298A1 (de)
KR (1) KR20110038011A (de)
CA (1) CA2729696A1 (de)
ES (1) ES2527768T5 (de)
IL (1) IL210322A (de)
PL (1) PL2586782T5 (de)
PT (1) PT2586782E (de)
RU (1) RU2519717C2 (de)
WO (1) WO2010000469A2 (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015170340A3 (en) * 2014-05-06 2016-03-31 Laurus Labs Private Limited Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2324027B1 (de) 2008-07-29 2016-02-24 Medichem, S.A. Neue kristalline salzformen eines 5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a] pyrazinderivats
WO2010117738A2 (en) * 2009-03-30 2010-10-14 Teva Pharmaceutical Industries Ltd. Solid state forms of sitagliptin salts
EA022485B1 (ru) * 2009-08-13 2016-01-29 Сандоз Аг КРИСТАЛЛИЧЕСКОЕ СОЕДИНЕНИЕ 7-[(3R)-3-АМИНО-1-ОКСО-4-(2,4,5-ТРИФТОРФЕНИЛ)БУТИЛ]-5,6,7,8-ТЕТРАГИДРО-3-(ТРИФТОРМЕТИЛ)-1,2,4-ТРИАЗОЛО[4,3-a]ПИРАЗИНА
CA2800507A1 (en) 2010-03-31 2011-10-06 Teva Pharmaceuticals Industries Ltd. Solid state forms of sitagliptin salts
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
EP2407469A1 (de) * 2010-07-13 2012-01-18 Chemo Ibérica, S.A. Sitagliptinsalz
US20130158265A1 (en) * 2010-08-27 2013-06-20 Dhananjay Govind Sathe Sitagliptin, salts and polymorphs thereof
WO2012076973A2 (en) 2010-12-09 2012-06-14 Aurobindo Pharma Limited Novel salts of dipeptidyl peptidase iv inhibitor
CN102153559B (zh) * 2011-02-28 2013-04-24 南京工业大学 一种合成磷酸西他列汀及其衍生物的方法
SG10201405403QA (en) 2011-03-03 2014-11-27 Cadila Healthcare Ltd Novel salts of dpp-iv inhibitor
SI2691083T1 (sl) 2011-03-29 2017-12-29 Krka, D.D., Novo Mesto Farmacevtski sestavek sitagliptina
EP2726484A1 (de) 2011-06-29 2014-05-07 Ranbaxy Laboratories Limited Feste dispersionen von sitagliptin und verfahren zu ihrer herstellung
EP2726483A1 (de) 2011-06-30 2014-05-07 Ranbaxy Laboratories Limited Neuartige salze aus sitagliptin
SI2736909T1 (sl) 2011-07-27 2017-08-31 Farma Grs, D.O.O. Proces za pripravo sitagliptina in njegovih farmacevtsko sprejemljivih soli
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (de) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridin-4-carbonsäureamidderivate als kinaseinhibitoren
US9181256B2 (en) 2011-10-14 2015-11-10 Laurus Labs Private Ltd. Salts of sitagliptin, process for the preparation and pharmaceutical composition therefore
WO2013084210A1 (en) 2011-12-08 2013-06-13 Ranbaxy Laboratories Limited Amorphous form of sitagliptin salts
ES2421956B1 (es) 2012-03-02 2014-09-29 Moehs Ibérica S.L. Nueva forma cristalina de sulfato de sitagliptina
EP2911655A1 (de) 2012-10-24 2015-09-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Tpl2-kinasehemmer zur vorbeugung oder behandlung von diabetes und zur förderung des überlebens von betazellen
EP2769712A1 (de) 2013-02-21 2014-08-27 Siegfried International AG Pharmazeutische Formulierung mit DPP-IV-Agglomeraten und DPP-IV-Hemmerpartikeln
WO2015001568A2 (en) * 2013-07-01 2015-01-08 Laurus Labs Private Limited Sitagliptin lipoate salt, process for the preparation and pharmaceutical composition thereof
HUE043472T2 (hu) 2013-12-17 2019-08-28 Sun Pharmaceutical Ind Ltd Eljárás kristályos szitagliptin-fumarát elõállítására
IN2014MU00212A (de) 2014-01-21 2015-08-28 Cadila Healthcare Ltd
WO2015114152A1 (en) 2014-02-03 2015-08-06 Galenicum Health S.L. Stable pharmaceutical compositions containing sitagliptin in the form of immediate release tablets
IN2014MU00651A (de) * 2014-02-25 2015-10-23 Cadila Healthcare Ltd
CN105461721B (zh) * 2014-08-25 2018-09-18 正大天晴药业集团股份有限公司 一种二肽基肽酶-4抑制剂的晶体
WO2016046679A1 (en) * 2014-09-28 2016-03-31 Mohan M Alapati Compositions and methods for the treatment of diabetes and pre-diabetes
CZ27898U1 (cs) 2015-01-13 2015-03-02 Zentiva, K.S. Krystalická modifikace 2 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4,]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu
CZ27930U1 (cs) 2015-01-13 2015-03-10 Zentiva, K.S. Krystalická modifikace 3 L-vínanu (3R)-3-amino-1-[3-(trifluormethyl)-6,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrazin-7-yl]-4-(2,4,5-trifluorfenyl)butan-1-onu
KR101684053B1 (ko) 2015-01-20 2016-12-08 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 신규 결정형 및 이의 제조방법
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
KR20170036288A (ko) 2015-09-24 2017-04-03 주식회사 종근당 시타글립틴의 신규염 및 이의 제조방법
KR102484846B1 (ko) * 2015-11-27 2023-01-05 한림제약(주) 벤조피란 유도체의 정제방법, 이의 결정형 및 상기 결정형의 제조방법
KR101829706B1 (ko) * 2016-09-21 2018-02-19 씨제이헬스케어 주식회사 벤즈이미다졸 유도체의 산부가염
MX2016016260A (es) 2016-12-08 2018-06-07 Alparis Sa De Cv Nuevas formas solidas de sitagliptina.
CN106892832B (zh) * 2017-03-14 2019-06-25 珠海联邦制药股份有限公司 一种西格列汀杂质及其制备方法
EP3781261A4 (de) * 2018-04-17 2022-02-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Orale pharmazeutische zusammensetzungen mit dpp-4-inhibitor
TR201910633A1 (tr) * 2019-07-17 2021-05-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Si̇taglipti̇n i̇çeren efervesan tablet kompozi̇syonu
WO2023139276A1 (en) 2022-01-24 2023-07-27 Zaklady Farmaceutyczne Polpharma S.A. Process for preparing crystalline sitagliptin hydrochloride monohydrate

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19616486C5 (de) 1996-04-25 2016-06-30 Royalty Pharma Collection Trust Verfahren zur Senkung des Blutglukosespiegels in Säugern
UA74912C2 (en) 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
WO2004087650A2 (en) † 2003-03-27 2004-10-14 Merck & Co. Inc. Process and intermediates for the preparation of beta-amino acid amide dipeptidyl peptidase-iv inhibitors
JO2625B1 (en) 2003-06-24 2011-11-01 ميرك شارب اند دوم كوربوريشن Phosphoric acid salts of dipeptidyl betidase inhibitor 4
JP2007504230A (ja) 2003-09-02 2007-03-01 メルク　エンド　カムパニー　インコーポレーテッド ジペプチジルペプチダーゼ−ｉｖ阻害剤のリン酸塩の新規結晶性形態
EP1667524A4 (de) 2003-09-23 2009-01-14 Merck & Co Inc Neue kristalline form eines phosphorsäuresalzes eines hemmstoffs der dipeptidylpeptidase iv
WO2005072530A1 (en) 2004-01-16 2005-08-11 Merck & Co., Inc. Novel crystalline salts of a dipeptidyl peptidase-iv inhibitor
WO2006033848A1 (en) 2004-09-15 2006-03-30 Merck & Co., Inc. Amorphous form of a phosphoric acid salt of a dipeptidyl peptidase-iv inhibitor
EP1909776A2 (de) † 2005-07-25 2008-04-16 Merck & Co., Inc. Dodecylsulfatsalz eines dipeptidyl-peptidase-iv-hemmers
AU2006292377B2 (en) * 2005-09-20 2011-03-03 Emisphere Technologies, Inc. Use of a DPP-IV inhibitor to reduce hypoglycemic events
KR20070111099A (ko) * 2006-05-16 2007-11-21 영진약품공업주식회사 시타글립틴 염산염의 신규 결정형, 이의 제조 방법과 이를포함하는 약학적 조성물
EP2599781A1 (de) * 2007-12-20 2013-06-05 Dr. Reddy's Laboratories Ltd. Verfahren zur Herstellung von Sitagliptin und pharmazeutisch akzeptablen Salzen daraus
EP2324027B1 (de) * 2008-07-29 2016-02-24 Medichem, S.A. Neue kristalline salzformen eines 5,6,7,8-tetrahydro-1,2,4-triazolo[4,3-a] pyrazinderivats
WO2010117738A2 (en) † 2009-03-30 2010-10-14 Teva Pharmaceutical Industries Ltd. Solid state forms of sitagliptin salts

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2010000469A2 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015170340A3 (en) * 2014-05-06 2016-03-31 Laurus Labs Private Limited Novel polymorphs of sitagliptin hydrochloride, processes for its preparation and pharmaceutical composition thereof

Also Published As

Publication number Publication date
PL2586782T3 (pl) 2015-04-30
ES2527768T5 (es) 2018-02-08
IL210322A (en) 2015-04-30
IL210322A0 (en) 2011-03-31
EP2650298A1 (de) 2013-10-16
EP2915814A3 (de) 2015-10-07
EP2915814A2 (de) 2015-09-09
ES2527768T3 (es) 2015-01-29
WO2010000469A3 (en) 2010-11-18
EP2586782B2 (de) 2017-10-04
PL2586782T5 (pl) 2018-05-30
KR20110038011A (ko) 2011-04-13
RU2519717C2 (ru) 2014-06-20
EP2650296A1 (de) 2013-10-16
EP2586782A1 (de) 2013-05-01
CA2729696A1 (en) 2010-01-07
PT2586782E (pt) 2015-02-03
EP2650297A1 (de) 2013-10-16
EP2586782B1 (de) 2014-10-29
WO2010000469A2 (en) 2010-01-07
RU2011103249A (ru) 2012-08-10
EP2650299A1 (de) 2013-10-16

Similar Documents

Publication Publication Date Title
EP2586782B2 (de) Kristalline Salze von Sitagliptin
US20090247532A1 (en) Crystalline polymorph of sitagliptin phosphate and its preparation
CZ2001775A3 (cs) Krystalické formy EtO2C-CH2-(R)Cgl-Aze-Pab-OH
WO2009102226A1 (en) Malonic acid salt of 5-[[4-[2-(methyl-2-pyridinylamino)ethoxy]phenyl]methyl]- 2,4-thiazolidinedione
US20230167113A1 (en) Crystalline forms of gepotidacin
AU765614B2 (en) A substantially crystalline form of melagatran
US8143409B2 (en) Crystalline form of rabeprazole sodium
KR20230141899A (ko) [(1S)-1-[(2S,4R,5R)-5-(5-아미노-2-옥소-티아졸로[4,5-d]피리미딘-3-일)-4-하이드록시-테트라하이드로퓨란-2-일]프로필]아세테이트의 고체 형태
CA2164296C (en) Heterocyclic chemistry
JP5336509B2 (ja) （ｒ）−３−フルオロフェニル−３，４，５−トリフルオロベンジルカルバミン酸１−アザビシクロ［２．２．２］オクト−３−イルエステルの安定な結晶性塩
WO2002060441A1 (en) Novel forms of 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo (1,2-a)pyridine-6-carboxamide
WO2002060442A1 (en) Novel forms of 2,3-dimethyl-8-(2-ethyl-6-methylbenzylamino)-imidazo (1,2-a)pyridine-6-carboxamide
EP4085062A1 (de) Neuartige salze und/oder co-kristalle von tenofovir-alafenamid
CA3215792A1 (en) Processes for the synthesis of valbenazine
EP3210975A1 (de) Cokristalle von lorcaserin
WO2012066366A1 (en) New salts suitable for the preparation of pharmaceutical compositions
MXPA01002044A (en) CRYSTALLINE FORMS OF EtO2

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20110131

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO SE SI SK SM TR

AX Request for extension of the european patent

Extension state: AL BA RS

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130117

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20130730